Form 4 filings across 1 company. Net figures count open-market buys and sales only. EDGAR profile ↗
Lifetime net: +$47.7K
Reported holding is the most recent post-transaction share count on a Table I row.
How quickly this filer reports. Section 16 allows two business days from the transaction.
All 15 filings we hold were filed within the two-business-day deadline.
Counted in business days from the transaction date, or the deemed execution date where the filing reports one, excluding weekends and federal holidays. How this is measured · All late filings
The 23 most recent Form 4 transactions.
| Aug 18 | ACRV | Acrivon Therapeutics, Inc. | SSELL | 1,229 | $2.01 | $2.5K | <0.1% | Open the original filing on SEC.gov |
| May 21 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 13,729 | $1.79 | $24.6K | -0.6% | Open the original filing on SEC.gov |
| May 18 | ACRV | Acrivon Therapeutics, Inc. | AGRANT | 72,706 | — | — | +23.2% | Open the original filing on SEC.gov |
| May 18 | ACRV | Acrivon Therapeutics, Inc. | AGRANT | 180,095 | — | — | +8.7% | Open the original filing on SEC.gov |
| May 14 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 490 | $1.92 | $941 | -0.2% | Open the original filing on SEC.gov |
| May 14 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 1,253 | $1.92 | $2.4K | <0.1% | Open the original filing on SEC.gov |
| Mar 1 | ACRV | Acrivon Therapeutics, Inc. | AGRANT◆ | 185,495 | — | — | — | Open the original filing on SEC.gov |
| Mar 1 | ACRV | Acrivon Therapeutics, Inc. | AGRANT◆ | 417,210 | — | — | — | Open the original filing on SEC.gov |
| Feb 21 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 14,265 | $1.53 | $21.8K | -0.7% | Open the original filing on SEC.gov |
| Feb 14 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 579 | $1.63 | $944 | -0.2% | Open the original filing on SEC.gov |
| Feb 14 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 1,302 | $1.63 | $2.1K | <0.1% | Open the original filing on SEC.gov |
| Jan 14 | ACRV | Acrivon Therapeutics, Inc. | PBUY | 49,000 | $1.68 | $82.1K | +2.4% | Open the original filing on SEC.gov |
| Nov 21, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 19,904 | $2.30 | $45.8K | -1.0% | Open the original filing on SEC.gov |
| Nov 14, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 490 | $2.24 | $1.1K | -0.2% | Open the original filing on SEC.gov |
| Nov 14, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 59,765 | $2.24 | $133.9K | -2.8% | Open the original filing on SEC.gov |
| Aug 21, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 19,905 | $1.32 | $26.3K | -0.9% | Open the original filing on SEC.gov |
| Aug 14, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 490 | $1.39 | $681 | -0.2% | Open the original filing on SEC.gov |
| Aug 14, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 59,766 | $1.39 | $83.1K | -2.7% | Open the original filing on SEC.gov |
| May 21, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 19,904 | $1.15 | $22.9K | -0.9% | Open the original filing on SEC.gov |
| May 14, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 491 | $1.14 | $560 | -0.2% | Open the original filing on SEC.gov |
| May 14, 2025 | ACRV | Acrivon Therapeutics, Inc. | FTAX | 59,766 | $1.14 | $68.1K | -2.6% | Open the original filing on SEC.gov |